. Author manuscript; available in PMC: 2016 Mar 11.

Published in final edited form as: J Neurooncol. 2016 Jan 4;127(1):165–171. doi: 10.1007/s11060-015-2028-2

Table 1.

Demographic, clinical and treatment data by pre- and post-2004

	Total (n = 196)	Pre-2004 (n = 74)	Post-2004 (n = 122)	p value
Average age (SD) (year)s	46.6 (14.6)	46.2 (14.9)	46.9 (14.4)	0.75
Gender (n, % male)	112 (57 %)	45 (61 %)	67 (55 %)	0.46
Ethnicity (n, %)
White	170 (87 %)	61 (82 %)	109 (89 %)	0.17
Black	17 (9 %)	7 (9 %)	10 (8 %)
Other	9 (4 %)	6 (9 %)	3 (3 %)
KPS > 60 (n, %)	157 (80 %)	59 (80 %)	98 (80 %)	1.00
Surgery (n, %)
Biopsy	60 (31 %)	27 (36 %)	33 (27 %)	0.39
STR	73 (37 %)	25 (34 %)	48 (39 %)
GTR	63 (32 %)	22 (30 %)	41 (34 %)
Chemotherapy agent (n, %)
Temozolomide	116 (59 %)	1 (1 %)	115 (94 %)	<0.001
PCV	2 (1 %)	2 (3 %)	0 (0 %)
Gliadel^®	7 (3 %)	6 (8 %)	1 (1 %)

SD standard deviation, KPS Karnofsky performance status, STR subtotal resection, GTR gross total resection, cGy centigray, PCV procarbazine, lomustine and vincristine